Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRent ExpenseShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Alterity Therapeutics (ATHE) Shares Outstanding (2016 - 2025)

Alterity Therapeutics has reported Shares Outstanding over the past 2 years, most recently at $603.0 million for Q2 2019.

  • For Q2 2019, Shares Outstanding rose 49.19% year-over-year to $603.0 million; the TTM value through Jun 2019 reached $603.0 million, up 49.19%, while the annual FY2019 figure was $603.0 million, 49.19% up from the prior year.
  • Shares Outstanding for Q2 2019 was $603.0 million at Alterity Therapeutics, up from $4.2 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $603.0 million in Q2 2019 and troughed at $404.2 million in Q2 2018.
  • A 4-year average of $202.6 million and a median of $4.2 million in 2018 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 368.57% in 2018 and later surged 49.19% in 2019.
  • Year by year, Shares Outstanding stood at $465813.1 in 2016, then skyrocketed by 93.6% to $901823.1 in 2017, then skyrocketed by 368.57% to $4.2 million in 2018, then soared by 14169.86% to $603.0 million in 2019.
  • Business Quant data shows Shares Outstanding for ATHE at $603.0 million in Q2 2019, $4.2 million in Q4 2018, and $404.2 million in Q2 2018.